StockData
Lantern Pharma Inc. logo

Lantern Pharma Inc. (LTRN) stock

LTRNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 17, 2026Score 5/30
$0.36−0.02 (-6.17%)

Close on Nov 17, 2026Market cap $4.67MP/E –Yield –

Earnings

Lantern Pharma's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.

Next report
Nov 12, 2026
Q3 FY2026 · estimated, before the open
Revenue, Q2 FY2026
–
EPS, Q2 FY2026
$0.57
-$0.40 a year earlier
Latest guidance
None
No outlook given in releases

Quarterly results

Revenue and earnings per share from each of Lantern Pharma's earnings releases, newest first

QuarterReportedRevenueYoYEPSSource
Q3 FY2026ended Sep 30, 2026Nov 12, 2026Expected––––
Q2 FY2026ended Jun 30, 2026Aug 14, 2026before the open––$0.57Release
Q1 FY2026ended Mar 31, 2026May 15, 2026after the close––-$0.30Release
Q4 FY2025ended Dec 31, 2025Mar 30, 2026after the close–––Release
Q3 FY2025ended Sep 30, 2025Nov 13, 2025before the open–––Release
Q2 FY2025ended Jun 30, 2025Aug 13, 2025after the close––-$0.40Release
Q1 FY2025ended Mar 31, 2025May 15, 2025before the open––$0.42Release
Q4 FY2024ended Dec 31, 2024Mar 27, 2025after the close––-$0.54Release
Q3 FY2024ended Sep 30, 2024Nov 7, 2024after the close––-$0.42Release
Q2 FY2024ended Jun 30, 2024Aug 8, 2024after the close––-$0.46Release
Q1 FY2024ended Mar 31, 2024May 9, 2024after the close––$0.51Release
Q4 FY2023ended Dec 31, 2023Mar 18, 2024after the close––$0.39Release

Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.

Guidance

Lantern Pharma has not given guidance in its releases

Many companies give their outlook only on the conference call or not at all. When Lantern Pharma puts a forecast in an earnings release, it is listed here with the exact sentence.

Press releases

Releases Lantern Pharma filed with the SEC as exhibits to Form 8-K or 6-K

  1. Results
  2. Update
  3. Update
  4. Results
  5. Results
  6. Update
  7. Update
  8. Results
  9. News
  10. News
  11. Update
  12. Results
  13. Results
  14. Update
  15. Results

See a number that looks wrong?